# QL Biopharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ql-biopharm

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.qlbiopharm.com
- Total disclosed funding: $130M
- Latest round: Series C (Sep 14, 2026)
- Investors on record: 31

## About

Based in Beijing, China and established in 2018, Beijing QL Biopharmaceutical Co., Ltd., trading as QL Biopharm, operates as a recombinant protein drug provider, focusing on the production of recombinant protein drugs. Xujia Zhang, the founder and the CEO of the company, was a researcher at the Institute of Biophysics, Chinese Academy of Sciences. The core members of the company's research and development team used to work at Novo Nordisk, Gan & Lee and other pharmaceutical companies. QL Biopharm has established a research and development center in Beijing and a production base in Taizhou, China. It was awarded honors such as Specialized, Refined, Featured and Original SMEs in Beijing and National High-tech Enterprise. 
In September 2026, QL Biopharm raised nearly CNY 300 million in Series C+ funding led by Cathay Capital, with participation from Huatai Zijin Investment, Tencent Investment and Elikon Venture.


The company's technology platforms include QL Fold, QL Long, QL Fusion and QL Oral. The company has 10 recombinant protein innovators and biosimilars under development in its product pipeline, including two international class I innovators and one large biosimilar. QL Biopharm's drugs can be used to treat diabetes, obesity, non-alcoholic steatohepatitis and other diseases.

The company generates revenue from providing recombinant protein drugs.

## Funding rounds

- Series C, Sep 14, 2026 — Cathay Capital, Huatai Zijin Investment, Elikon Venture, Tencent Investment
- Series C, Mar 2, 2026, $73M — OrbiMed Advisors, Qiming Venture Partners, 5Y Capital, Huagai Capital, Lanchi Ventures, TF Capital, Apricot Capital, TigerYeah Capital
- Series C, Jan 26, 2026 — Legend Star
- Series C, Feb 17, 2025, $14M — Lanchi Ventures, New Investment Group, IMEik
- Series B, Nov 27, 2023, $28M — Chengdu Science and Technology Venture Capital Group, Lanchi Ventures, Grandway Capital, Chengdu Venture Capital, Kinsight Capital, China-U.S. Green Fund, IMEik
- Series B, Mar 5, 2023 — Lanchi Ventures, Elikon Venture, Taizhou China Medical City New Drug Fund Management, Taizhou Huayin Gold Investment, Bridge Hill Capital, MF Capital, Shenzhen Tiande Investment Co., Ltd
- Series A, May 25, 2021 — Hong Shan, CMB International Asset Management, BioTrack Capital
- Series A, Oct 27, 2020, $15M — Hong Shan, BioTrack Capital, Beijing Cuihu Investment Management, TigerYeah Capital, E Link Ventures
- Angel, Apr 2, 2019 — Legend Star, TF Capital, BioTrack Capital, Qitai Fangzhou (Ningbo) Information Technology

## Investors

- Legend Star (https://capitalatlas.ai/funds/legend-star) — Angel, Series C
- TF Capital — Angel, Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Angel, Series A
- Qitai Fangzhou (Ningbo) Information Technology — Angel
- Hong Shan — Series A
- Beijing Cuihu Investment Management — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A, Series C
- E Link Ventures (https://capitalatlas.ai/funds/e-link-ventures) — Series A
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- Lanchi Ventures (https://capitalatlas.ai/funds/lanchi-ventures) — Series B, Series C
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B, Series C
- Taizhou China Medical City New Drug Fund Management (https://capitalatlas.ai/funds/taizhou-china-medical-city-new-drug-fund-management) — Series B
- Taizhou Huayin Gold Investment — Series B
- Bridge Hill Capital — Series B
- MF Capital (https://capitalatlas.ai/funds/mf-capital) — Series B
- Shenzhen Tiande Investment Co., Ltd — Series B
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series B
- Grandway Capital (https://capitalatlas.ai/funds/grandway-capital) — Series B
- Chengdu Venture Capital (https://capitalatlas.ai/funds/chengdu-venture-capital) — Series B
- Kinsight Capital (https://capitalatlas.ai/funds/kinsight-capital) — Series B
- China-U.S. Green Fund — Series B
- IMEik — Series B, Series C
- New Investment Group (https://capitalatlas.ai/funds/new-investment-group) — Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series C
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series C
- Cathay Capital — Series C
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series C
- Tencent Investment — Series C